← All trials
NCT05012397
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- Aug 31, 2024
- Completion date
- Aug 31, 2024
- First posted
- Aug 19, 2021
- Last posted
- Nov 10, 2021
- Enrollment
- 65
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Rain Therapeutics Inc.Lead sponsor
Drugs studied
Indications studied
- Adenocarcinoma of Lung
- Squamous Cell Carcinoma of Head and Neck
- Biliary Tract Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Transitional Cell
- Uterine Cervical Neoplasms
- Gene Amplification
- Melanoma
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Sarcoma
- Stomach Neoplasms
- Testicular Neoplasms
- Adrenocortical Carcinoma
- Cholangiocarcinoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.